For this class, Tofé et al. [30] reported a decrease in BMI for patients with T2DM treated with GLP-1 RAs at 6 months (37.05 ± 6.1 kg/m2) and at 12 months (37.21 ± 6.8 kg/m2) as compared to their initial visit (38.56 ± 6.6 kg/m2), p < 0.001, results that are similar to the ones from our study when comparing V6M to V0M and V12M to V0M (Table 3, Table 4 and Table 5). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.